Cellectis to Report Third Quarter Financial Results on November 12, 2026
Globe Newswire•09/11/2026•16:30 ET
1
Key Highlights
- ➤Cellectis (CLLS, ALCLS) will report Q3 2026 financial results November 12 after U.S. market close
- ➤Investor conference call and webcast scheduled November 13 at 8:00 a.m. ET / 2:00 p.m. CET
- ➤Cellectis develops genetic medicines using gene, base, epigenetic and transcriptional editing
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, will report financial results for the third quarter 2026 ending September 30, 2026 on Thursday, November 12, 2026 after the close of the U.S. market.
The publication will be followed by an investor conference call and webcast on Friday, November 13, 2026, at 8:00 a.m. ET / 2:00 p.m. CET. The call will include the Company’s third quarter 2026 results and an update on business activities. Details for the call are as follows:
Get started
Create a free account to read the full story.